Unlocking Better Health Worldwide
What started as a vision to make quality medicines accessible has grown into a global pharmaceutical organization. Rooted in Chicago and operating in more than 25 countries, Aardvark Pharma is committed to developing, manufacturing, and distributing life-changing treatments — with patients at the center of every decision.
Developing
Aardvark Pharma's Developing vertical is one of three core revenue streams and focuses on pharmaceutical development services. It covers four key areas:
- Chemical Compounds — Specializes in developing high-quality chemical compounds with precision and consistency.
- BE (Bioequivalence) Studies — Conducts studies to verify that generic or alternative products are safe, effective, and reliable substitutes.
- Clinical Trials — Offers end-to-end clinical trial services, spanning study design through data analysis, to support product development and regulatory approval.
- Dossier Compliance — Ensures all regulatory documentation meets global requirements, facilitating smooth market approvals across different jurisdictions.
In short, this vertical positions Aardvark as a full-service development partner — from compound creation and testing to the regulatory paperwork needed to bring a drug to market.
Manufacturing
Aardvark Pharma's Manufacturing vertical highlights their production capabilities and quality standards across three key areas:
- SRA and GMP Approved Facilities — Facilities are fully approved by Stringent Regulatory Authorities (SRAs) and comply with Good Manufacturing Practice (GMP) standards, ensuring consistent quality and regulatory compliance.
- Sterile and Non-Sterile Drugs — Manufacturing both sterile and non-sterile drug products, demonstrating versatility across different drug categories and production requirements.
- 2000 Liter Capacity for Sterile Drugs — The facility has a large-scale 2000-liter production capacity specifically for sterile drugs, enabling them to handle high-volume manufacturing demands.
In short, this vertical establishes Aardvark as a capable, compliant, and scalable manufacturer — equipped to handle a broad range of pharmaceutical products while meeting rigorous international regulatory standards.
Distribution
Aardvark Pharma's Distribution vertical covers their global reach and compliance-driven logistics across four key areas:
- Global Distribution — We distribute to SRAs and Rest of World (ROW) markets through our international offices in Chicago, London, Dubai, Hyderabad, and Buenos Aires, ensuring broad geographic coverage.
- Storage and Transport Compliance — Adhering to strict storage and transport conditions using data loggers, and conduct transport validation studies to ensure product integrity throughout the supply chain.
- Marketing and Tender Participation — Actively engaging in government tenders and private-sector marketing through key opinion leaders (KOLs), pharmacies, and hospitals, enabling strong market penetration.
- Post-Marketing Monitoring — We manage post-marketing surveillance of Adverse Drug Event Reports (ADERs) and maintain a robust pharmaco vigilance plan to ensure ongoing product safety after market launch.
In short, this vertical positions Aardvark as a compliant, globally connected distributor — capable of reaching diverse markets while maintaining product quality, regulatory adherence, and long-term safety monitoring.
Aardvark signs contract to distribute 16 drugs in UAE
Aardvark Pharma will initiate the registration process with MOHAP for 16 drugs from its portfolio and will receive commercial milestone payments (October 2023).
Aardvark signs distribution agreement in Saudi Arabia
Aardvark Pharma begins registration with Saudi FDA for 6 drugs from its portfolio and receives commercial milestones (September 2021).
Aardvark begins R&D for 10 drugs for its USA portfolio
Aardvark Pharma initiates research to register 10 oncology drugs with the US FDA by 2032 (October 2025).
“
Every Medicine we bring to market is a promise kept - to patients, to progress, and to a healthier world.”
Suraj Khatau
Managing Director at Aardvark
